Description
Bremelanotide, also known as PT-141, is a synthetic peptide analogue of alpha-melanocyte-stimulating hormone (α-MSH). It is a cyclic heptapeptide with the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. As a melanocortin receptor agonist, bremelanotide non-selectively activates several melanocortin receptors, primarily MC3-R and MC4-R in the central nervous system. This activation is believed to modulate inflammatory pathways and influence sexual arousal and desire.
PT-141 has been most extensively researched for its role in treating hypoactive sexual desire disorder (HSDD) in premenopausal women, for which it has received FDA approval. It is also being investigated for its potential in treating erectile dysfunction (ED) in men, particularly for those who do not respond to traditional PDE5 inhibitors. The unique mechanism of action, which works through the central nervous system, makes it a promising area of study for sexual dysfunction.
This product is intended for research purposes only and is not for human consumption. It should be handled by qualified professionals in a laboratory setting.
CAS: 189691-06-3
PubChem CID: 9941379
Molecular Formula: C₅₀H₆₈N₁₄O₁₀
Molecular Weight: 1025.16 g/mol
Amino Acid Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH (7 aa, cyclic)
Physical Form: Lyophilized Powder
Purity: ≥99%
Storage: -20°C, protected from light and moisture

